Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
3.285
+0.025 (0.77%)
Nov 5, 2024, 1:24 PM EST - Market open
Fulcrum Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for FULC stock have an average target of 7.44, with a low estimate of 2.00 and a high estimate of 15. The average target predicts an increase of 126.48% from the current stock price of 3.29.
Analyst Consensus: Hold
* Price targets were last updated on Sep 13, 2024.
Analyst Ratings
The average analyst rating for FULC stock from 10 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 1 | 1 |
| Buy | 4 | 4 | 4 | 4 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy → Hold Downgrades $15 → $4 | Buy → Hold | Downgrades | $15 → $4 | +21.77% | Sep 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $17 → $4 | Strong Buy → Hold | Downgrades | $17 → $4 | +21.77% | Sep 13, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $4 | Buy → Hold | Downgrades | $4 | +21.77% | Sep 12, 2024 |
| B of A Securities | B of A Securities | Hold → Sell Downgrades $10 → $2 | Hold → Sell | Downgrades | $10 → $2 | -39.12% | Sep 12, 2024 |
| Stifel | Stifel | Strong Buy → Hold Downgrades $22 → $3 | Strong Buy → Hold | Downgrades | $22 → $3 | -8.68% | Sep 12, 2024 |
Financial Forecast
Revenue This Year
81.96M
from 2.81M
Increased by 2,821.96%
Revenue Next Year
n/a
from 81.96M
EPS This Year
-0.28
from -1.59
EPS Next Year
-1.24
from -0.28
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 87.0M | n/a | 90.7M | ||
| Avg | 82.0M | n/a | 55.8M | ||
| Low | 78.4M | n/a | 10.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3,000.6% | - | - | ||
| Avg | 2,822.0% | - | - | ||
| Low | 2,695.0% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.07 | -0.49 | -0.33 | ||
| Avg | -0.28 | -1.24 | -1.30 | ||
| Low | -0.56 | -2.78 | -3.58 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.